Award Number: W81XWH-051-0329

TITLE: Enhancing Involvement in Treatment Decision Making by Women with Breast Cancer

PRINCIPAL INVESTIGATOR: Mary Ann O'Brien
Timothy Whelan
Amiram Gafni
Cathy Charles, Ph.D.
Peter Ellis, Ph.D.

CONTRACTING ORGANIZATION: McMaster University
Hamilton, Ontario, Canada L8N 3Z5

REPORT DATE: July 2007

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Enhancing Involvement in Treatment Decision Making by Women with Breast Cancer

Mary Ann O'Brien, Timothy Whelan, Amiram Gafni, Cathy Charles, Ph.D., Peter Ellis, Ph.D.

Email: maryann.obrien@hrcc.on.ca

McMaster University
Hamilton, Ontario, Canada L8N 3Z5

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Purpose: Women with breast cancer desire more information about their disease, in part, to be involved in making treatment decisions (TDs). Patient involvement responds to patients’ desires for autonomy and addresses ethical concerns about rights to make TDs. However, several researchers have reported that patients’ actual experiences in TDM did not match their preferences. The study objectives are to 1) understand the meaning of involvement in TDM from the perspectives of women with early stage breast cancer (ESBC); 2) identify stages/steps of TDM used by women and their physicians during the treatment consultation(s); and 3) identify the behaviors of women and physicians that facilitate or impede women’s involvement in TDM. Methods: A qualitative approach with interviews and video-stimulated recall is being used. In Phase 1, interviews with 19 women with ESBC were held to understand the concept of involvement in TDM. In Phase 2, surgical (n=6) or medical oncology (MO) consultations (n=15) with new ESBC patients were videotaped. Subsequently, women and medical oncologists or surgeons separately viewed their consultation. Interviews were taped, transcribed, and analyzed. Findings: Phase 1: Most women wanted high quality information soon after diagnosis but many felt isolated and uninformed until the surgical or the medical oncology visit. In Phase 2, most women described an iterative TDM process where they made a preliminary treatment decision prior to the consultation, often based upon experiences of family or friends. Clinicians described many behaviours used to facilitate the patient’s involvement in TDM. While women reported some of these behaviours, they also reported fewer or different behaviours than clinicians. Significance: The information from this study will be useful to patients and physicians for promoting patient involvement. It can be used to develop and evaluate training programs for both physicians and patients to involve patients with cancer in decisions about their care.

14. ABSTRACT

15. SUBJECT TERMS

Treatment Decision Making, Video-Stimulated Recall Interviews, Patient Participation, Behavior Identification

16. SECURITY CLASSIFICATION OF:

17. LIMITATION OF ABSTRACT

18. NUMBER OF PAGES

19. NAME OF RESPONSIBLE PERSON

U

UU

UU

USAMRMC

U

UU

UU
# Table of Contents

- Introduction .............................................................................................................3
- Body ......................................................................................................................3
- Key Research Accomplishments ........................................................................7
- Reportable Outcomes ..........................................................................................7
- Conclusions ..........................................................................................................8
- References ...........................................................................................................8
- Appendices ...........................................................................................................9
Introduction

This report summarizes the research accomplishments of the second year of the Predoctoral Traineeship Award, from July 1, 2006 to June 30, 2007. The training studentship is a doctoral degree in Health Research Methodology at McMaster University in Hamilton, Canada.

The overall goal of the thesis proposal is to improve the opportunity for patient involvement in treatment decision making (TDM) for women with early stage breast cancer (ESBC). The specific objectives are 1) to describe the meaning of involvement in TDM from the perspectives of women with ESBC, 2) to identify the processes or stages of TDM used by women and their physicians and 3) to identify the behaviors of women and their physicians that facilitate or impede women’s involvement in TDM. In this report, the results of Task 2 (Objective 2) from the Statement of Work will be summarized. The second task was to complete patient recruitment, data collection and analysis for the Phase 2 patient and clinician interviews.

Statement of Work Task 2, Phase 2 (Video-Stimulated Recall Interviews with Patients and Physicians: Patient Recruitment, Data Collection, and Analysis (Months 10-24))

Patient Recruitment: A process for patient recruitment was developed in Phase 1. A similar process was used in Phase 2. Briefly, the PI met with medical oncologists as well as surgeons to explain the purpose of Phase 2 of the study. The PI also presented the study to the primary nurses who were part of the clinical team to gain their support for the study and to enlist their help with the process to be used to identify eligible patients. The clinical features of all new patients were reviewed and those who appeared to meet the inclusion criteria (refer to the Phase 2 Eligibility Form in the Appendices) were identified by a research assistant. Prior to each eligible patient’s scheduled visit, the oncologist or surgeon was asked for his or her permission to approach the patient about the study and for his/her consent to participate in the study. If the clinician agreed, then the patient was approached by the oncologist, surgeon or the primary nurse. If the patient expressed interest in the study, then a research assistant explained the purpose of the study and obtained consent. For consenting patients and clinicians, the consultation was videotaped. Subsequently, women and surgeons or medical oncologists separately viewed their videotaped consultation with the researcher. While watching their video, each woman and clinician was interviewed by the researcher about the consultation process. The video was paused at various pre-selected stopping points to facilitate discussion of TDM and key clinician facilitators and barriers. The setting for the study was a regional cancer centre.
(Juravinski Cancer Centre (JCC)) and a teaching hospital (St. Joseph’s Hospital) in Hamilton, Ontario.

**Data Collection**

Pilot – Testing: The interview guide was pilot-tested with five patients who were completing chemotherapy treatment. Subsequently, the guide was revised (refer to the Phase 2 Interview Guide in the Appendices). Data collection for the study began shortly thereafter.

All patients who signed a consent form were interviewed by the PI using the revised interview guide. Interviews were held either at the JCC, McMaster University or in the patient’s home according to the patient’s preference. Each interview was audiotaped and transcribed verbatim. In addition, demographic and clinical data were collected. After each interview, notes were handwritten then transcribed.

In general, patients were selected to be approached for the study if they met the inclusion criteria and the clinician agreed to approach the patient. As well, patients were selected in a purposeful manner so that both node-negative and node-positive patients in different age groups were included among women making an adjuvant therapy decision.

**Analysis**

The analysis was conducted using a grounded theory approach (Charmaz 2006; Glaser and Strauss 1967). A brief coding guide developed for Phase 1 was adapted for Phase 2. Two analysts independently coded two entire transcripts. The codes were compared and agreement was reached. In a similar manner, categories were generated from the codes, the results were compared, and agreement was reached. To check the stability of the process, a section from a third transcript was coded independently by the same two analysts and the results were compared. One analyst coded the remaining transcripts. Substantive coding was used to identify themes and sub-themes from the data. Selective coding was used to identify a central theme and causal conditions that influenced the central theme and resulting actions.

**Results**

Twenty-two women with ESBC were enrolled in this phase and 21 completed the study. Fifteen women made a decision about adjuvant therapy and six made a decision about surgery. One patient was excluded after videotaping because of a tape failure. Of the women who made
an adjuvant therapy decision, six had node negative disease and nine had node positive
disease.

The following section highlights several examples of themes in the categories of
stages/steps of TDM and clinician facilitators and barriers to women’s involvement in TDM.

A. Stages/Steps of Treatment Decision Making

Most women described an iterative TDM process in which information was gathered from
informal networks and preferred and non-preferred treatment options were identified prior to
formal consultations. Preferred treatment options were confirmed or reassessed at the surgical
and MO consultations after receiving information from the specialist. Surgical decisions were
confirmed in the surgeon’s office on the same day. In contrast, most women described
deliberation process about adjuvant treatment both during the MO consult and at home with a
treatment decision reached at home several days after the MO consult. Most women continued
to revisit their treatment decision after the formal surgical or MO consultation.

Prior to the surgical and MO consultations, women sought information about treatment
options from informal networks of family or friends.

Prior to the surgical consult, there was no systematic process whereby women accessed
high quality information about treatment options. Women obtained information about surgical
options from their informal network. Before the MO consult, most women described fears about
chemotherapy based on others’ negative experiences. Many women thought chemotherapy was
only offered in serious cases and others thought that it might shorten their life.

Most women identified preferred and non-preferred treatment options prior to formal
consultations.

Women wanted treatment that would give them the best chance of eliminating cancer.
They considered their family doctors’ preferences for treatment and opinions about treatment
effectiveness from family and friends. Regarding surgery, women identified a preferred type of
surgery before the consultation which was later confirmed with the surgeon. In contrast, most
women had a preference for or against chemotherapy in general but not the type of
chemotherapy. In both surgical and MO settings, women did not change their preferred option
after the formal consultation unless new or conflicting information was received.
Discussions with the surgeon were important to subsequent TDM. During the surgical follow-up visit, women formed an opinion about the ‘aggressiveness’ of the cancer and the need for further treatment. If women heard the surgeon mention that chemotherapy might be offered by the medical oncologist, they were prepared for any subsequent discussion. If treatment options or tumor-related information given by the medical oncologist were different from those expected, it was confusing for women.

Chemotherapy consultations were important to TDM but were also overwhelming and complex. Despite efforts by medical oncologists to transmit information clearly, both women and oncologists believed that the consultations were information-dense. Women were overwhelmed by the amount of information and found it difficult to think about treatment options during the consultation. Women frequently misinterpreted or forgot information given.

B. Clinician Facilitators and Barriers to Women’s Involvement in TDM

Women’s Views: Facilitators
The most common facilitators were:
- Prepared her for chemotherapy discussion (family doctor and surgeon)
- Made her feel comfortable e.g. making eye contact, friendly and relaxed manner
- Gave clear explanations about the disease, risk of recurrence (MO), and treatment options
- Encouraged her to process information about options e.g. explaining the DM context, using visual aids, and encouraging her to take enough time
- Gave her a clear treatment recommendation which helped her focus on options that were most suited to her preferences
- Provided reassurance by stating that he/she agreed with her decision

Women’s Views: Barriers
Generally few clinician barriers were mentioned. The most commonly noted barriers were insufficient use of visual aids by clinicians, mismatch of information in discussion and take home material, and not acknowledging women’s expectations. Women also mentioned system barriers including lack of access to information prior to surgical and MO consults.

Clinicians’ Views
Clinicians described similar categories but more facilitating behaviours related to information-giving and processing than women. Clinicians relied on verbal explanations rather than visual aids. They described fewer interpersonal behaviors such as making women feel comfortable and providing reassurance.

Key Research and Training Accomplishments

1. Successfully competed all PhD course requirements with an ‘A’ standing or higher (previous report).
2. Successfully completed the PhD comprehensive examination (previous report).
3. Thesis related tasks:
   a. Completed Phase 1 data collection (previous report).
   b. Developed a process to videotape consultations of women with ESBC.
   c. Completed pilot testing for Phase 2.
   d. Completed Phase 2 interviews of 21 women with ESBC and their oncologist or surgeon. These interviews identified stages/steps in TDM used by these women as clinician facilitators and barriers to their involvement in TDM.
4. As part of my training program, I participated in other research projects that resulted in podium or poster presentations at conferences.
5. Also as part of my training program, I reviewed several manuscripts and a national grant application in conjunction with my supervisor.

Reportable Outcomes

Conference Presentation Abstracts


Awards

2007    Juravinski Cancer Centre. Student Research Day. One of four best research presentations.

Conclusions

In summary, considerable progress has been made during the second year of the Predoctoral Traineeship Award as noted in the section on Key Research and Training Accomplishments. We were able to successfully recruit patients and clinicians from the JCC and St. Joseph’s Hospital. Data collection is complete for Phase 2 and an analysis has been conducted. As contained in the previous report, all PhD course requirements have been successfully completed as has the comprehensive examination. The study has received the support from the oncologists and nurses at the JCC as well as surgeons at HHS and St. Joseph’s Hospital. This support was crucial to the successful completion of the video-stimulated recall interviews.

References


Appendices

1. Phase 2 Eligibility Form
2. Phase 2 Interview Guide
3. CV
4. Abstracts
Appendices
Enhancing Involvement in Treatment Decision Making by Women with Breast Cancer

Patient Initials: ___ ___  Phase 2  Study ID Number: ___ ___ ___

ELIGIBILITY ASSESSMENT
To be completed for all patients who meet the Inclusion Criteria

SECTION 1: INCLUSION CRITERIA

Answer EACH criterion listed below:

<table>
<thead>
<tr>
<th>The patient:</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a) Is female.</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>1b) Has histologically documented invasive carcinoma of the breast.</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>1c) Is Stage I, Stage II, or Stage III a and eligible for surgery, chemotherapy or radiation therapy.</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

If all answers are “Yes” continue to SECTION 2. If at least one “No” answer, patient is not eligible, do not continue.

SECTION 2: EXCLUSION CRITERIA

Answer EACH criterion listed below:

<table>
<thead>
<tr>
<th>The patient:</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a) Is Stage III b, c or Stage IV</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2b) Is unable to speak or understand English fluently (including visual impairment).</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2c) Is mentally incompetent including any psychiatric or addictive disorders that would preclude taking part in an interview.</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Continue to SECTION 3

SECTION 3: ELIGIBILITY STATUS

3a) Is the patient eligible to participate in the study?  
(i.e., all inclusion Criteria are answered “Yes” and all exclusion Criteria answered “No”)  

1 Yes → Continue to SECTION 4 PATIENT CONSENT  

2 No → Sign and date form
SECTION 4: PATIENT CONSENT

4a) Has the patient provided written informed consent?

☐ 1 Yes → Include

☐ 2 No → Please provide reason:

   ○ 1 Physician did not want the patient to be approached

   ○ 2 Patient did not want to consent

   ○ 3 Other: ________________________________

SECTION 5: Identification

Study ID Number: __ __ __ __

Cancer Centre Chart Number: __ __ · ____________

Date of Eligibility Assessment __ __ / __ __ __ / __ __ __ __
  day  month  year

Signature of person completing form: ________________________________

Date form completed: __ __ / __ __ __ / __ __ __ __
  day  month  year
Study Title: Enhancing Involvement in Treatment Decision Making by Women with Breast Cancer

Phase 2: Patient Interview Guide and Video- Stimulated Recall

Greetings

Introduction

As you know, this is a study about how women make decisions about breast cancer treatment and how they want to be involved in that process. In this interview, you and I will have a short discussion about your decision making process, then we will watch a DVD of your consultation with Dr. _____. If there are any questions that you do not want to answer, we will just skip to the next question. If you would like to have a rest at any time, just let me know. After we watch the DVD, there are other questions that I will ask you about the decision making process.

Opening Question
1. From your perspective, did you have any goals for the consultation with Dr. ______? If yes, what were they? If no, what did you think would happen at the consultation? (this question was not used in Pilot but suggested by D. Feldman-Stewart Feb 2006 to provide context)

Decision making process related to cancer treatment

1. With respect to your consultation with Dr. ____ do you feel that there were decisions that were made about your treatment?
   Prompts: If yes, can you tell me about the decision that was made?
            If no, can you tell me why you felt there was no decision to be made?

Now, we will watch the DVD of your consultation with Dr. _____. I want you to stop the DVD any time that you feel that you or the doctor was taking part in the process of making a decision about treatment. I also want you to stop the DVD if the doctor was doing anything or saying anything that either helped you to take part or made it harder for you to take part in the process of decision making. [Give instructions to the patient]

[Watch DVD]

[After the DVD, the following questions will be asked if they were not addressed while watching the DVD]

If there was a decision about treatment
2. In your situation, can you describe the process of making the decision about treatment?
Prompts: Possibilities: asking for and receiving information about treatment options, deliberating over the options, making the decision.
Alternative questions: How was a decision about treatment made? How did you decide what to do?

3. Were there clear steps that you went through in order to make this decision?
   a. Prompts: If Yes what were the steps?
   b. If yes, how do these steps relate to each other (a sequence, steps happening simultaneously?)
   c. Was one step more important than another?
   d. If No, how did you arrive at a treatment decision?

4. The doctor gave you some information about the chance of the cancer returning. Did you use this information in your decision making process?
   a. Prompts: If yes, how did your use this information?
   b. Prompts: If no, why was that?

5. The doctor gave you some information about side effects of treatment. Did you use this information in your decision making process?
   a. Prompts: If yes, how did your use this information?
   b. Prompts: If no, why was that?

6. Who was involved in the process of making the decision?
Prompts: Patient, doctor, primary care nurse, family, others?

7. Where did the process of decision making take place?
Prompts: At home, at the cancer centre, both places?

8. When did the process of decision making first start?
Prompts: When patient had symptoms, at the oncologist’s office

9. When did the process of decision making end?

10. In summary, did you feel that you took part in the process of making a treatment decision?
Prompts: If yes, can you tell me all the ways that you took part? Was it how you wanted to take part?
Prompts: If no, why was that? Did you take part more than you wanted or less than you wanted? If more than you wanted, how did that happen? How did you feel about taking part more than you wanted? If less than you wanted, how did that happen? What sort of things prevented you from taking part?
11. If you took part in the process of making a decision as much as you wanted, did the doctor say or do anything to help you to take part in the process of making a decision about treatment?

12. Did the doctor say or do anything to discourage you from taking part in the process of making the decision about treatment?

13. Is there any feature about you as a person that helped you to take part in the process of making the decision about treatment?
   *Prompts:* For example, a patient who wants to know all treatment details or does not want to know; The patient’s previous personal or family member’s experience.

14. Is there any feature about you as a person that acted as a barrier to you taking part in making a decision about treatment?

15. Did your involvement in the process of making a decision about treatment change since you first learned you had breast cancer?
   *Prompts:* When you saw the surgeon, when you saw the oncologist

16. Did you have enough time to take part in the process of making a decision about treatment?

17. Overall, now thinking about the decision making process, what is needed for a process that is high in quality?
   *Prompt:* what did you find helpful in the decision making process?

18. How would you describe the quality of the decision making process that you used?
   *Prompt:* Why do you feel this way?

**Closing**

19. Is there anything else you would like to tell me about your situation of making a treatment decision?

Thank you once again for participating in my study.
Instructions:

Now, we will watch the DVD of your consultation with Dr. ____.

I want you to stop the DVD any time if

1. You feel that you were taking part in the process of treatment decision making.

2. You feel that the doctor was taking part in the process of treatment decision making.

3. The doctor did or said anything that helped you to take part in the process of treatment decision making.

4. The doctor did anything or said anything that made it harder for you to take part in the process of treatment decision making.
NAME: O’Brien (Thomson), Mary Ann

ADDRESS: Business
Supportive Cancer Care Research Unit
Juravinski Cancer Centre
699 Concession Street
Hamilton, Ontario
L8V 5C2
voice mail: (905) 387-9711 ext 64502
email: maryann.o'brien@hrcc.on.ca

EDUCATIONAL BACKGROUND
2003 PhD in progress (commenced September 2003)
1995 MSc (Design, Measurement and Evaluation), McMaster University, Hamilton, Canada
1984 BHSc (Physiotherapy) McMaster University, Hamilton, Canada
1978 Diploma in Physiotherapy, Mohawk College, Hamilton, Canada
Certificate in Physiotherapy, McMaster University, Hamilton, Canada

CURRENT STATUS AT MCMASTER UNIVERSITY
2001-2006 Associate Clinical Professor, School of Rehabilitation Science
1998-2001 Assistant Clinical Professor, School of Rehabilitation Science
1992-1997 Clinical Lecturer, School of Rehabilitation Science

EMPLOYMENT HISTORY

ACADEMIC
2000- 2003 Senior Research Manager, Supportive Cancer Care Research Unit, McMaster University
1999- 2000 Research Co-ordinator, Evidence-based Practice Centre, McMaster University
1998-1999 Research Co-ordinator, McMaster University and Social and Public Health Services Division, Region of Hamilton-Wentworth
1997-1998 Senior Research Fellow, Department of Public Health, University of Aberdeen, United Kingdom
1996-1997 Research Fellow, Department of Health Sciences and Clinical Evaluation, University of York, United Kingdom
1985-1991 Clinical Education Co-ordinator, Mohawk-McMaster Physiotherapy Program, Mohawk College of Applied Arts and Technology, Hamilton, Ontario

CLINICAL
1999- Physiotherapist, Hamilton Health Sciences
1996-1997 Evaluation Specialist, Re-engineering Department, Chedoke-McMaster Hospitals
1991-1996  Education Manager, Physiotherapy Services, Chedoke-McMaster Hospitals
1985-1991  Clinical Education Co-ordinator, Chedoke-McMaster Hospitals, McMaster University Medical Centre Division
1983-1985  Senior Physiotherapist, Chedoke-McMaster Hospitals, McMaster University Medical Centre Division
1978-1983  Staff Physiotherapist, Chedoke-McMaster Hospitals, McMaster University Medical Centre Division

AWARDS AND FELLOWSHIPS

2004 – 2006  Doctoral Fellowship, Canadian Breast Cancer Foundation – Ontario Chapter (declined Year 2)
2004 – 2007  Doctoral Studentship, National Cancer Institute of Canada (declined)
2004 – 2005  Ontario Graduate Student Award, (declined)

SCHOLARLY AND PROFESSIONAL ACTIVITIES

1997-      Peer Reviewer
          Grants: National Health Service Research & Development Programme, National Health Service Health Technology Assessment Programme, United Kingdom
          Manuscripts: American Journal of Public Health, Health and Social Care in the Community, Journal of Epidemiology and Community Health, Medical Care, Quality in Health Care
1995-2002  Member, Board of Examiners, Physiotherapy National Exam.
1991-1995  Member, Clinical Education Group, Physiotherapy Programme, School of Occupational Therapy and Physiotherapy, McMaster University, Hamilton, Ontario.
1990-1995  Chair, Station Development Sub-Committee, OSCE Test Construction and Implementation, Canadian Alliance of Physiotherapy Regulatory Boards.

AREAS OF INTEREST

RESEARCH
Attributes of the clinical encounter that facilitate treatment decision-making
Effectiveness of interventions to improve health professional practice
Factors influencing the adoption of research evidence into health professional practice

TEACHING
Finding the best available evidence and incorporating it in clinical practice
COURSES TAUGHT

McMaster University (Graduate)
2004-  Lecturer, Inquiry Seminar, MSc. PT Programme
2003- 2003 Tutor, Unit Three, Introduction to Cardio-pulmonary and Neurology, MCISc PT Programme
2000 Co-Advisor with A Jadad, Research Internship, Health Research Methods Programme

University of Aberdeen (Graduate)
1997 Lecturer, Health Services Research

McMaster University (Undergraduate)
2001 Tutor, Unit Four, Cardio-pulmonary, BHSc. PT Programme
2000- 2003 Inquiry Seminar, BHSc. PT Programme
2000 Advisor, Unit Six Research Internship
1998-1999 Tutor, Unit Four, Cardio-pulmonary, BHSc. PT Programme
1996 Advisor, Unit Six, Independent Study, BHSc. PT Programme
1993-1995 Tutor, Unit Four, Cardio-pulmonary, BHSc. PT Programme
1992 Advisor, Block Six, Independent Study, BHSc. PT Programme
1990-1992 Tutor, Block One, Introduction to Musculo-Skeletal Problems, BHSc. PT Programme
1988 Tutor, H.S. 4B4/3B4, Health, Science and Society, BHSc Programme

Other
1988-1995 Tutor, Clinical Teaching Workshop, Program for Faculty Development, McMaster University, Hamilton, Ontario

Thesis Committee
2000  Jodi Herold. The effect of using an alternative method to calculate station cut scores in an objective structured clinical examination (OSCE). (Masters) University of Toronto.

LIFETIME RESEARCH FUNDING

GRANTS

Funded

Funding Agency: Canadian Health Services Research Foundation
Funding Period: November 1 2004 to October 31 2006
Project Title: A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community

Funding Agency: Ontario Ministry of Health and Long-Term Care
Funding Period: January 2004 – June 2004
Project Title: e-Health and mental Health Services: A synthesis of literature to identify best practices.

Funding Agency: Ministry of Health and Long Term Care
Funding Period: April 1 2003-March 31 2004
Funds Held in Department of Clinical Epidemiology and Biostatistics
Project Title: An Evaluation of the Effectiveness of a Specialized Nursing Case Management Program in Coordinating Supportive Cancer Care in the Community.
Investigators: Sussman J, O’Brien MA, Howell, D, Whelan T.

Funding Agency: Hamilton Regional Cancer Centre Foundation
Funding Period: April 1 2003- March 31 2004
Funds Held at the Hamilton Regional Cancer Centre
Project Title: Can Physicians Accurately Record Breast Cancer Outcomes? A Quality Improvement Pilot Study.

Funding Agency: Ministry of Health and Long Term Care
Funding Period: April 1 2001-March 31 2003
Funds Held in Department of Clinical Epidemiology and Biostatistics
Project Title: Identifying the best model to provide (coordinate) supportive cancer care in the community
Investigators: Brazil K, Whelan T, O’Brien MA, Sussman J, Pyette N.

Funding Agency: Agency for Healthcare Research and Quality
Funding Period: April 1 2001-March 31 2002
Funds Held in Department of Clinical Epidemiology and Biostatistics
Project Title: Diffusion and Dissemination of Evidence-based Cancer Control Interventions

Funding Agency: Agency for Healthcare Research and Quality
Funding Period: April 1 2000-March 31 2001
Funds Held in Department of Clinical Epidemiology and Biostatistics
Project Title: Impact of Cancer-related Decision Aids

Funding Agency: Agency for Healthcare Research and Quality
Funding Period: September 30 1999-September 29 2000
Funds Held in Department of Clinical Epidemiology and Biostatistics
Project Title: Management of Chronic Central Neuropathic Pain Following Spinal Cord Injury
Investigators: Jadad A, O’Brien MA, Snider A, Gauld M
Funding Agency: Canadian Health Services Research Foundation
Funding Period: November 1999-November 2000

Project Title: Improving Communication Among Public Health Researchers and Decision and Policy Makers.
Investigators: Thomas BJ, O'Brien MA, Edwards N., Ciliska D., Dobbins M., Beyers J.

Funding Agency: CMH Physiotherapy Grant Fund
Funding Period: July 1996-July 1997
Funds Held in CMH Physiotherapy Department
Project Title: Diagnostic Validity of Clinical Tests in Temporomandibular Disorder: meta-analyses
Investigators: Gross A, Haines T, Goldsmith C, McIntosh J, Thomson MA.

Funding Agency: Heart and Stroke Foundation of Ontario
Funding Period: July 1996-July 1998
Project Title: Stroke Strengthening Study

Funding Agency: National Health Service, Research and Development, United Kingdom
Funding Period: January 1996 - January 1997
Funds held at University of York, United Kingdom
Project Title: The Effectiveness of Continuing Education Conferences in Improving Health Professional Performance and Health Care Outcomes
Investigators: Thomson MA, Freemantle N, Oxman AD, Davis DA.

Funding Agency: Canadian Orthopaedic Foundation, Hip, Hip Hooray Grants Program
Funding Period: July 1995-July 1996
Funds Held in CMH Physiotherapy Department
Project Title: Diagnostic Validity of Clinical Tests in Temporomandibular Disorder: meta-analyses (1995 update)
Investigators: Gross A, Haines T, Goldsmith C, McIntosh J, Thomson MA.

Funding Agency: Canadian Orthopaedic Foundation, Hip, Hip Hooray Grants Program
Funding Period: July 1993 - June 1994
Funds held in Physiotherapy Department, Chedoke-McMaster Hospitals
Project Title: Lower Extremity Function Study
Investigators: Thomson MA, Moreland J, Balsor B, Kay, T.

Funding Agency: Edith Herman Research Fund, McMaster University, Hamilton, Ontario
Funding Period: December 1993 - December 1994
Funds held in Faculty of Health Sciences, School of Occupational and Physiotherapy
Project title: Diagnostic Validity of Clinical Tests in Temporomandibular Disorders: Meta-analyses
Investigators: Gross A, Haines T, Goldsmith C, McIntosh J, Thomson MA.

Funding Agency: Hamilton District Research Fund, Ontario Physiotherapy Association, Hamilton, Ontario
Funding Period: June 1992 to June 1993
Funds held by Hamilton District Treasurer
Project title: Diagnostic Validity of Clinical Tests in Temporomandibular Disorders: Meta analyses
Investigators: Gross A, Haines T, Goldsmith C, McIntosh J, Thomson MA.

Funding Agency: Hamilton District, Ontario Physiotherapy Association
Funding Period: January 1992 - December 1992
Funds held in Physiotherapy Department, Chedoke-McMaster Hospitals
Project Title: The Efficiency of EMG Biofeedback for Upper Extremity Function Following Stroke: A meta-analysis.
Investigators: Moreland J, Thomson MA.

Submitted
Funding Agency: CIHR
Funding Period: October 1 2006 – September 30, 2011
Funds held in Department of Surgery, McMaster University
Project Title: Tailored Knowledge Exchange in Rectal Cancer (TKRC) Trial

Unfunded
Title: The efficiency of EMG biofeedback for lower extremity function following stroke: a meta-analysis. Investigators: Moreland J, Thomson MA, Fuoco A. Location: Chedoke-McMaster Hospitals

PUBLICATIONS

Peer Reviewed


2003

2003

2002
Denkers M, Biagi H, O'Brien MA, Jadad AR, Gauld M. Dorsal root entry zone (DREZ) lesioning to treat central neuropathic pain (CNP) in traumatic spinal cord injured (TSCI) patients: a systematic review. SPINE 2002;27(7):E177-E184

2001

2001

1999

1999

1998

1998

1998

1998

1998

1998

1997

1997  Thomson MA, Oxman AD, Haynes RB, Davis DA, Freemantle N, Harvey EL. Local opinion leaders to improve the effectiveness of health professional practice and health outcomes. Cochrane Library [Update Software], Effective Professional Practice Review Group.

1997  Thomson MA, Oxman AD, Haynes RB, Davis DA, Freemantle N, Harvey EL. Audit and feedback (Parts I and II) to improve the effectiveness of health professional practice and health outcomes. Cochrane Library [Update Software], Effective Professional Practice Review Group.


Conference Proceedings


2001  Oxman AD; Grimshaw JM, O'Brien MA. Analysing complexity: experience from the Effective Practice and Organisation of Care (EPOC) reviews. 10th Annual Cochrane Colloquium, Lyon, France.

1999  Brunton G, O'Brien MA, Thomas BH, McNair S. Searching for Evidence in public health research. 7th Annual Cochrane Colloquium, Rome Italy.

1998 Fraser C, Thomson MA. Identifying non-randomised studies in Medline. 6th Annual Cochrane Colloquium, Baltimore, USA.


1997 Thomson MA, Oxman AD, Grimshaw JM, Bero LA. Helping to bridge the gap between research and practice in decisions about how to ensure the delivery of effective health services. Scientific Basis of Health Services Conference, Amsterdam, The Netherlands.


Book Chapter


1998 Bero L, Grilli R, Grimshaw J, Harvey E, Oxman A, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to


Not Peer Reviewed


Peer-Reviewed Reports


PRESENTATIONS

Peer Reviewed


2002   Sussman J, Whelan TJ, Grunfeld E, Sellick S, Fitch M, O'Brien MA, Schiff S. Development and testing of an instrument to measure client awareness of supportive care cancer services as an outcome measure in a study of supportive cancer networks. 14th International Symposium, Supportive Care in Cancer, Boston, MA.


1999   Thomas, BH, O'Brien, MA, Ciliska, D, Brunton, G, McNair, S. Tightening the connection among public health policy research evidence and practice. The 3rd International Conference on the Scientific Basis of Health Services, Toronto, Canada.


1997   Thomson MA, Grimshaw JM, Greener J. Complexity in systematic reviews. 5th Annual Cochrane Colloquium, Amsterdam, The Netherlands.

1997   Mowatt G, Thomson MA, Grimshaw JM, Grant A. Implementing early warning messages. European Workshop: Scanning the horizon for emerging health technologies, Copenhagen, Denmark.


1996   Thomson MA, Oxman AD, Haynes RB, Davis DA, Freemantle N, Harvey EL. The effectiveness of outreach visits to improve health professional practice and health care outcomes. Prevention in Primary Care Conference, Newcastle, UK.

1996   Thomson MA, Oxman AD, Haynes RB, Davis DA, Freemantle N, Harvey EL. The effectiveness of audit and feedback to improve health professional practice and health care outcomes. Prevention in Primary Care Conference, Newcastle, UK.

1996   Thomson MA, Oxman AD, Haynes RB, Davis DA, Freemantle N, Harvey EL. The effectiveness of local opinion leaders to improve health professional practice and health care outcomes. Prevention in Primary Care Conference, Newcastle, UK.

1994  Thomson MA, Oxman AD, Haynes RB, Davis DA. No magic bullets: A systematic review of 102 trials of interventions to help health care professionals deliver services more effectively or efficiently. 2nd Annual Cochrane Colloquium, Hamilton, ON.


Invited

2006  O’Brien MA. Through the looking glass: using video stimulated recall to examine women’s decision making experiences about breast cancer treatment. Hôpital St. François Assise, Québec City, Québec, Canada


2000  O’Brien MA, Updating your Cochrane review. Canadian Cochrane Centre Workshop. Evidence-based Practice Centre, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.


2000  O’Brien MA, Using non-randomized studies in Cochrane Effective Practice and Organisation of Care (EPOC) reviews. Non Randomized Studies Symposium. Copenhagen, Denmark

1999  O’Brien MA, The trials and tribulations, and benefits of being a Cochrane reviewer. Canadian Cochrane Colloquium, Department of Clinical Epidemiology and Biostatistics, McMaster University.


1997  Thomson MA, Heart Save Project, London, UK


1997  Thomson MA, Effectiveness of interventions to improve health professional practice. Health Services Research Unit, University of Aberdeen, UK.

1997  Thomson MA, Effectiveness of educational outreach visits to improve professional practice. PACE/CCEPP Joint Meeting. London, UK.


1996  Thomson MA, Educational issues and methods. Teaching and Learning in the Clinical Setting, Program for Faculty Development. McMaster University

1995  Thomson MA, Providing constructive feedback. Teaching and Learning in the Clinical Setting, Program for Faculty Development. McMaster University


Through the looking glass: using video-stimulated recall to examine women’s decision making experiences about breast cancer treatment

O’Brien MA¹, Whelan T¹, Charles C², Ellis P¹, Gafni A², Lovrics, P³, Hasler A¹, Dimitry S¹.
Supportive Cancer Care Research Unit, McMaster University, Hamilton, ON¹
Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, ON²
St. Joseph’s Hospital, Hamilton, ON, CANADA³

Background: Women with breast cancer (BC) desire information, in part, to be involved in treatment decision making (TDM). However, several researchers have reported that patients’ actual experiences in TDM did not match their preferences. This study’s objectives were to identify stages/steps of TDM used by women with BC and to identify physicians’ behaviours that facilitated or impeded women’s involvement in TDM.

Methods: A qualitative approach with video-stimulated recall interviews was used. Surgical (n=6) or medical oncology (MO) consultations (n=15) with new BC patients were videotaped. Subsequently, women and physicians separately viewed their consultation. Interviews were taped, transcribed, and analyzed.

Results: Most women described an iterative TDM process where they made a preliminary treatment decision prior to the consultation, often based upon experiences of family or friends. Women wanted high quality information soon after diagnosis to assist with TDM but many felt uninformed prior to the consultation. Clinicians described many behaviours used to facilitate the patient’s involvement in TDM. While women reported some of these behaviours, they also reported fewer or different behaviours than clinicians. Some women perceived that family physicians and surgeons helped their involvement in TDM in subsequent MO consultations.

Conclusion: Many women perceived that they did not receive information relevant for TDM when it was most useful. Clinicians and women have different views of how clinicians facilitated women’s involvement in TDM. Family physicians and surgeons are important in the TDM process by ensuring that women have early access to high quality information about different aspects of treatment.

Word count: 249
What can physicians do to promote patient involvement in decision making (DM) in the oncology consultation

Ellis PM, Dimitry S, Charles C, O’Brien MA, Whelan TJ.

Background
Promoting patient involvement in DM is a desirable attribute of the oncology consultation. Greater involvement in DM may lead to improved patient satisfaction and reduced psychological morbidity. However, there is little empiric evidence on physician behaviors to promote patient involvement in treatment DM. This study used qualitative methods to identify physician characteristics important for patient involvement in DM.

Methods
We undertook semi-structured interviews with 11 medical and 10 radiation oncologists, plus 19 patients with breast, lung, GI, or GU cancers to determine physician attributes that promote patient involvement in DM. Interviews were audiotaped and transcribed verbatim, then analyzed independently by two researchers using predetermined coding rules. Individual attributes describing physician behaviors were identified and coded into common themes. These data were reviewed by an additional 37 patients participating in one of six focus groups.

Results
A total of 231 individual physician attributes were identified by physicians (179) and patients (52) that might facilitate patient involvement in DM. Common themes about physicians’ behavior identified from the interviews include: assess patient’s understanding and preferences, provide information, explain DM process, provide information on treatment options, allow time to consider treatment options, physicians’ communication skills and personality, check patient understanding of options, seek patient input into decision, be empathic.

Conclusions
Physicians and patients identify a large number of physician attributes to promote patient involvement in DM. These include both skills that are important in general physician-patient communication, as well as skills that are specifically related to the decision making process. Further research is needed to determine the relative importance of these factors.
Women with breast cancer have indicated a desire for more information about their disease, in part, to be involved in making treatment decisions. Importantly, patients who are involved in treatment decision making (TDM) are more likely to have their preferences incorporated in the treatment decision. Despite patients’ desires to be involved in TDM and the ethical and medical importance of this involvement, researchers have reported that patients’ actual experiences in making decisions did not match their preferences. The study objectives are to 1) understand the concept of involvement in TDM from the perspectives of women with early stage breast cancer (ESBC); 2) identify any stages or steps of DM used by women and their physicians during the treatment consultation(s); and 3) identify the behaviours of women and physicians that facilitate or impede women’s involvement in TDM. A qualitative approach with interviews and video-stimulated recall was used. In Part 1, interviews with 19 women with ESBC were held to develop the concept of involvement in TDM and the decision making process used by these women. In Part 2, treatment consultations of a second group of 20 women were digitally videotaped. Several days later, these women and their physicians (separately) viewed their own consultation to describe their DM process and identify the behaviours that facilitated or inhibited their involvement. All interviews were taped, transcribed verbatim and analyzed. Results: Part 1: Most women wanted high quality information soon after diagnosis but many felt that they were left in a void until the surgical or even the medical oncology visit. Most women thought they were heavily involved in a TDM process before, during and after the consultation. The results of the Part 2 pilot testing indicated that videotaping the consultation was feasible. Women liked the opportunity to review information presented in the consultation. They identified how they were involved in the DM process and different ways that the oncologist facilitated or inhibited their involvement. Conclusions: This study has identified women’s perceptions of their involvement in the TDM process, how treatment decisions were made and physicians’ behaviours that enhanced or impeded their involvement in TDM. This information will be useful to patients and physicians for promoting patient involvement in TDM.